John Robinson

Prof. John Robinson


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2010 in Science
Verified
Journal Article
Closed access
PDF file
NSNityakalyani Srinivas
Nityakalyani Srinivas
PJPeter Jetter
Peter Jetter
BUBernhard J. Ueberbacher
Bernhard J. Ueberbacher
MWMartina Werneburg
Martina Werneburg
KZKatja Zerbe
Katja Zerbe
JRJohn Robinson
John Robinson
Killing Pseudomonas: Gram-negative Pseudomonas bacteria are opportunistic pathogens, and drug-resistant strains present a serious health problem. Srinivas et al. (p. 1010 ) synthesized a family of peptidomimetic antibiotics that is active only against Pseudomonas . These antibiotics do not lyse the cell membrane, but instead target an essential outer membrane protein, LptD, which plays a role in the assembly of lipopolysaccharide in the outer cell membrane. Activity in a mouse infection model suggests that the antibiotics might have therapeutic potential. In addition, LptD is widely distributed in gram-negative bacteria and so its validation as a target has the potential to drive development of antibiotics with a broader spectrum of activity against gram-negative pathogens.

16 April 2008 in Accounts of Chemical Research
Verified
Journal Article
Closed access
JRJohn Robinson
John Robinson

1 January 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MUMatthias Urfer
Matthias Urfer
JBJasmina Bogdanovic
Jasmina Bogdanovic
FMFabio Lo Monte
Fabio Lo Monte
KMKerstin Moehle
Kerstin Moehle
KZKatja Zerbe
Katja Zerbe
JRJohn Robinson
John Robinson
Increasing antibacterial resistance presents a major challenge in antibiotic discovery. One attractive target in Gram-negative bacteria is the unique asymmetric outer membrane (OM), which acts as a permeability barrier that protects the cell from external stresses, such as the presence of antibiotics. We describe a novel β-hairpin macrocyclic peptide JB-95 with potent antimicrobial activity against Escherichia coli. This peptide exhibits no cellular lytic activity, but electron microscopy and fluorescence studies reveal an ability to selectively disrupt the OM but not the inner membrane of E. coli. The selective targeting of the OM probably occurs through interactions of JB-95 with selected β-barrel OM proteins, including BamA and LptD as shown by photolabeling experiments. Membrane proteomic studies reveal rapid depletion of many β-barrel OM proteins from JB-95-treated E. coli, consistent with induction of a membrane stress response and/or direct inhibition of the Bam folding machine. The results suggest that lethal disruption of the OM by JB-95 occurs through a novel mechanism of action at key interaction sites within clusters of β-barrel proteins in the OM. These findings open new avenues for developing antibiotics that specifically target β-barrel proteins and the integrity of the Gram-negative OM.

23 November 2007 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
FBFrancesca Boato
Francesca Boato
RTRichard M. Thomas
Richard M. Thomas
AGArin Ghasparian
Arin Ghasparian
AFAnnabelle Freund‐Renard
Annabelle Freund‐Renard
KMKerstin Moehle
Kerstin Moehle
JRJohn Robinson
John Robinson

17 July 2012 in ChemBioChem
Verified
Journal Article
Open access
PDF file
MWMartina Werneburg
Martina Werneburg
KZKatja Zerbe
Katja Zerbe
MJMario Juhas
Mario Juhas
LBLaurent Bigler
Laurent Bigler
USUrs Stalder
Urs Stalder
JRJohn Robinson
John Robinson
The asymmetric outer membrane (OM) of Gram‐negative bacteria contains lipopolysaccharide (LPS) in the outer leaflet and phospholipid in the inner leaflet. During OM biogenesis, LPS is transported from the periplasm into the outer leaflet by a complex comprising the OM proteins LptD and LptE. Recently, a new family of macrocyclic peptidomimetic antibiotics that interact with LptD of the opportunistic human pathogen Pseudomonas aeruginosa was discovered. Here we provide evidence that the peptidomimetics inhibit the LPS transport function of LptD. One approach to monitor LPS transport involved studies of lipid A modifications. Some modifications occur only in the inner membrane while others occur only in the OM, and thus provide markers for LPS transport within the bacterial envelope. We prepared a conditional lptD mutant of P. aeruginosa PAO1 that allowed control of lptD expression from the rhamnose promoter. With this mutant, the effects caused by the antibiotic on the wild‐type strain were compared with those caused by depleting LptD in the mutant strain. When LptD was depleted in the mutant, electron microscopy revealed accumulation of membrane‐like material within cells and OM blebbing; this mirrored similar effects in the wild‐type strain caused by the antibiotic. Moreover, the bacterium responded to the antibiotic, and to depletion of LptD, by introducing the same lipid A modifications, consistent with inhibition by the antibiotic of LptD‐mediated LPS transport. This conclusion was further supported by monitoring the radiolabelling of LPS from [14C]acetate, and by fractionation of IM and OM components. Overall, the results provide support for a mechanism of action for the peptidomimetic antibiotics that involves inhibition of LPS transport to the cell surface.

24 January 2013 in Journal of Peptide Science
Verified
Journal Article
Open access
PDF file
JRJohn Robinson
John Robinson
This review highlights the growing importance of protein epitope mimetics in the discovery of new biologically active molecules and their potential applications in drug and vaccine research. The focus is on folded β‐hairpin mimetics, which are designed to mimic β‐hairpin motifs in biologically important peptides and proteins. An ever‐growing number of protein crystal structures reveal how β‐hairpin motifs often play key roles in protein–protein and protein–nucleic acid interactions. This review illustrates how using protein structures as a starting point for small‐molecule mimetic design can provide novel ligands as protein–protein interaction inhibitors, as protease inhibitors, and as ligands for chemokine receptors and folded RNA targets, as well as novel antibiotics to combat the growing health threat posed by the emergence of antibiotic‐resistant bacteria. The β‐hairpin antibiotics are shown to target a β‐barrel outer membrane protein (LptD) in Pseudomonas sp., which is essential for the biogenesis of the outer cell membrane. Another exciting prospect is that protein epitope mimetics will be of increasing importance in synthetic vaccine design, in the emerging field of structural vaccinology. Crystal structures of protective antibodies bound to their pathogen‐derived epitopes provide an ideal starting point for the design of synthetic epitope mimetics. The mimetics can be delivered to the immune system in a highly immunogenic format on the surface of synthetic virus‐like particles. The scientific challenges in molecular design remain great, but the potential significance of success in this area is even greater. Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.